multiBIND biotec Overview

  • Founded
  • 2005
Founded
  • Status
  • Private
  • Latest Deal Type
  • Later Stage VC
  • Investors
  • 3

multiBIND biotec General Information

Description

Developer of chemical solvents intended for decontamination and disinfection. The company's solvents are used in molecular biology applications and prevent deoxyribonucleic acid and ribonucleic acid decontamination, enabling clients to treat surfaces, equipment in health institutions.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Specialty Chemicals
Other Industries
Industrial Chemicals
Primary Office
  • Gottfried-Hagen-Straße 62
  • 51105 Cologne
  • Germany
+49 0221 0000000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

multiBIND biotec Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Later Stage VC 01-Dec-2012 00000 Completed Generating Revenue
1. Early Stage VC 10-Apr-2006 00000 00000 Completed Generating Revenue
To view multiBIND biotec’s complete valuation and funding history, request access »

multiBIND biotec Executive Team (2)

Name Title Board Seat Contact Info
Thomas Lisowsky Ph.D Co-Founder, Patent Manager, Managing Director & Chief Executive Officer
You’re viewing 1 of 2 executive team members. Get the full list »

multiBIND biotec Board Members (1)

Name Representing Role Since
Wolfram Glock Sirius Venture Partners Member of the Advisory Board 000 0000
To view multiBIND biotec’s complete board members history, request access »

multiBIND biotec Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Intelligent Venture Capital Management Venture Capital Minority 000 0000 000000 0
Sirius Venture Partners Venture Capital Minority 000 0000 000000 0
High-Tech Gründerfonds Venture Capital Minority 000 0000 000000 0
To view multiBIND biotec’s complete investors history, request access »